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THE RELEVANCE OF CELL SIZE IN A CHO FED 
BATCH PROCESS
Dirk Martens1, Xiao Pan1, Abdulaziz Alsayyari1, Jos Hageman2, Rene Wijffels1,3, Ciska Dalm4
Background
The growth profile of a CHO cell fed-batch process can in general be 
divided into a growth phase followed by a stationary (non-growth) 
phase and a cell death phase. In a previous study an additional phase 
was observed between the cell proliferation and stationary phase 
during which cell numbers remained constant and cell size increased. 
The relevance of this cell size increase for the process performance as 
well as the cause for this shift in cell growth is, however, not clear.  
Results
Figure 3. Specifc productivity in the NI and SI 
phase expressed per cell and  per cell volume.
Figure 4. Cell specific productivity as a function 
of cell volume.
Objective
Establish the relevance of the switch from cell proliferation to cell size 
increase for fed-batch processes, obtain more insight in the 
physiological changes that occur and understand the underlying 
mechanisms that cause these changes. 
Methods
• CHO-K1 clone: BC-P producing an IgG 1
• Triplicate fed-batch cultures in 10 L bioreactors (Sartorius Stedim)
• DO: 50%, pH: 7.2±0.05 pH, T: 37 °C, N: 200 RPM.
• ActiCHO-P + ActiCHO feed A&B (GE Healthcare)
• Daily bolus feeding: 4.5% feed A + 0.45% feed B, glucose top-up to 
28 mM when lower than 18 mM.
• Metabolic flux modelling: Cobra toolbox for Matlab
• Transcriptomics: Affymetrix GeneChip™ CHO Gene 2.1 ST Arrays 
(Affymetrix, Santa Clara, USA)
• Cell cycle analysis: Cycletest™ Plus DNA Reagent Kit (BD 
Biosciences) & BD Accuri™ C6 Flow Cytometer (BD Biosciences).
Figure 2. Cell cycle distribution from day 
4,5,6 and 9.
Figure 1. Total viable cell number and total 
viable cell volume in the bioreactor. Top 
photos: Cells stained with bodipy (lipids)
Results
Figure 5. Metabolic flux distribution (mmol/109 cells/day) in the NI and SI phase. Green values 
indicate different fluxes whereas the red values indicate overlapping values based on flux 
variability analysis. 
Conclusions
• Day 4 to 6 cell proliferation stops and cells start increasing in size.
• Cells are arrested in the G1 phase.










• Cell size increase due to cell cycle arrest and continued growth.
– Arrest mainly in the G1 phase
– Down regulation cyclins and cyclin dependent kinases
– Upregulation mTOR activity
• Ratio of product to cellular protein increases from 1.5 to 5%.
• Yield of product on oxygen increases with a factor 1.5
Figure 6. Transcriptional regulation of pathways influencing cell size. SI phase compared to NI 
phase.
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